Suppr超能文献

基于体外摄取-转运数据预测缬沙坦在人体内的药代动力学特征。

Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.

机构信息

F. Hoffmann-La Roche Ltd., Non-Clinical Development, Drug Safety, CH-4070 Basel.

出版信息

Chem Biodivers. 2009 Nov;6(11):1975-87. doi: 10.1002/cbdv.200900116.

Abstract

The aim of this study was to evaluate a physiologically based pharmacokinetic (PBPK) model for predicting PK profiles in humans based on a model refined in rats and humans in vitro uptake-transport data using valsartan as a probe substrate. Valsartan is eliminated unchanged, mostly through biliary excretion, both in humans and rats. It was, therefore, chosen as model compound to predict in vivo elimination based on in vitro hepatic uptake-transport data using a fully mechanistic PBPK model. Plated rat and human hepatocytes, and cell lines overexpressing human OATP1B1 and OATP1B3 were used for in vitro uptake experiments. A mechanistic two-compartment model was used to derive the active and passive transport parameters, namely uptake Michaelis-Menten parameters (V(max) and K(m,u)) together with passive diffusion (P(dif)). These transport parameters were then used as input in a whole body physiologically based pharmacokinetic (PBPK) model. The uptake rate of valsartan was higher for rat hepatocytes (K(m,u)=28.4+/-3.7 microM, V(max)=1320+/-180 pmol/mg/min, and P(dif) =1.21+/-0.42 microl/mg/min) compared to human hepatocytes (K(m,u)=44.4+/-14.6 microM, V(max)=304+/-85 pmol/mg/min, and P(dif)=0.724+/-0.271 microl/mg/min). OATP1B1 and -1B3 parameters were correlated to human hepatocyte data, using experimentally established relative activity factors (RAF). Resulting PBPK simulations were compared for plasma- (humans and rats) and bile- (rats) concentration-time profiles following iv bolus administration of valsartan. Plasma clearances (CL(P)) for rats and humans were predicted within twofold relative to predictions based on respective in vitro data. The simulations were extended to simulate the impact of either OATP1B1 or -1B3 inhibition on plasma profile. The limited data set indicates that the mechanistic model allowed for accurate evaluation of in vitro transport data; and the resulting hepatic uptake transport kinetic parameters enabled the prediction of in vivo PK profiles and plasma clearances, using PBPK modelling. Moreover, the interspecies difference in elimination rate observed in vivo was correctly reflected in the transport parameters determined in vitro.

摘要

本研究旨在评估一种基于生理的药代动力学(PBPK)模型,该模型基于在大鼠和人体体外摄取-转运数据中经过优化的模型,以及缬沙坦作为探针底物,预测人体的 PK 曲线。缬沙坦在人和大鼠体内均以原形经胆汁排泄而消除,因此,选择缬沙坦作为模型化合物,根据体外肝摄取-转运数据,使用完全基于机制的 PBPK 模型预测体内消除。使用体外摄取实验,培养大鼠和人肝细胞以及过表达人 OATP1B1 和 OATP1B3 的细胞系。使用一个机械两室模型来推导主动和被动转运参数,即摄取米氏常数参数(V(max)和 K(m,u))以及被动扩散(P(dif))。然后,将这些转运参数用作全身生理基于药代动力学(PBPK)模型的输入。与人类肝细胞相比,大鼠肝细胞对缬沙坦的摄取速率更高(K(m,u)=28.4+/-3.7 microM,V(max)=1320+/-180 pmol/mg/min,P(dif)=1.21+/-0.42 microl/mg/min)。使用实验确定的相对活性因子(RAF),将 OATP1B1 和 -1B3 参数与人类肝细胞数据相关联。由此产生的 PBPK 模拟结果与大鼠和人体静脉内推注缬沙坦后的血浆(人和大鼠)和胆汁(大鼠)浓度-时间曲线进行了比较。与基于各自体外数据的预测相比,大鼠和人体的血浆清除率(CL(P))的预测值在两倍以内。模拟结果扩展到模拟 OATP1B1 或 -1B3 抑制对血浆曲线的影响。有限的数据表明,该机械模型允许对体外转运数据进行准确评估;并且由此产生的肝摄取转运动力学参数使使用 PBPK 建模能够预测体内 PK 曲线和血浆清除率。此外,体内观察到的消除率种间差异在体外确定的转运参数中得到了正确反映。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验